# reload+after+2024-01-21 17:43:33.260287
address1§100 Technology Square
address2§Sixth Floor
city§Cambridge
state§MA
zip§02139
country§United States
phone§617 914 8420
website§https://www.avrobio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§78
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Erik John Ostrowski M.B.A.', 'age': 51, 'title': 'President, Interim Chief Executive Officer, CFO & Treasurer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 947287, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Azadeh  Golipour Ph.D.', 'age': 44, 'title': 'Chief Technology Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 728207, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeffrey  Medin Ph.D.', 'title': 'Scientific Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven N. Avruch J.D.', 'age': 62, 'title': 'Chief Legal Officer & Secretary', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 506679, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Scott  Gottesman', 'title': 'Vice President of Human Resource', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andreas  Kouri', 'title': 'Senior Vice President of Global Supply Chain & External Manufacturing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Essra  Ridha FFPM, M.D.', 'age': 42, 'title': 'Chief Medical Officer', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kirsten  Dupuis', 'title': 'Chief of Staff', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§6
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.141
currency§USD
dateShortInterest§1702598400
forwardEps§-0.81
exchange§NMS
quoteType§EQUITY
shortName§AVROBIO, Inc.
longName§AVROBIO, Inc.
firstTradeDateEpochUtc§1529587800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a532199a-b6ec-3584-8874-430070002ccb
gmtOffSetMilliseconds§-18000000
targetHighPrice§2.0
targetLowPrice§2.0
targetMeanPrice§2.0
targetMedianPrice§2.0
recommendationMean§2.3
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§14.002
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
